Figure 1.

Time trends in imaging use among men with newly diagnosed prostate cancer by clinical risk categories. Low risk includes patients with tumors designated as clinical stage T1 to T2, Gleason score of 6 or less, and prostate-specific antigen (PSA) of less than 10ng/mL. Intermediate risk includes patients with tumors designated as clinical stage T1 to T2, Gleason score of 7, and/or PSA of 10 to 20ng/mL. High risk includes patients with tumors designated as clinical stage T3 and/or Gleason score of 8 to 10 and/or PSA greater than 20ng/mL. P values from generalized linear models with logit link. All statistical tests were two-sided.